Today, the Energy and Commerce Subcommittee on Health respected my May 12, request and held a hearing on racial disparities related to COVID-19. My goal for today’s hearing was for members to listen and take advantage of the opportunity to make a difference and change things for the better. I hope that the discussion today moves us in that direction. We should use this information to draft commonsense, bipartisan legislation that can become law.
During the hearing I was able to ask Dr. Roy and Dr. Brooks about how clinical trials will affect the development of a COVID-19 vaccine.
Agency Updates: The Food and Drug Administration (FDA) published a webpage on adverse event reporting for medical devices that are under emergency use authorization or mentioned in COVID-19 guidance documents.
The FDA revoked the emergency use authorization (EUA) of the Chembio Diagnostic System, Inc.’s DPP COVID-19 IgM/IgG System, an antibody test, due to concerns regarding the test’s accuracy.
The FDA posted template updates regarding the validation of molecular diagnostic tests for developers.
The Federal Communications Commission’s Wireline Competition Bureau approved an additional 62 funding applications to provide telehealth care during the pandemic – including two more locations in Texas.
Until next time, this is your doctor's note.
Congressman Michael C. Burgess, M.D.
